The content on this site is intended for healthcare professionals only
Click here to confirm you are a healthcare professionalI am not a healthcare professional. (By clicking on this button you will be taken to an external website).
| Clinical case study | |
| First-line options for aRCC | |
| Therapeutic approaches in the long term, after 18-24 months of therapy, considering the impact on QoL of manageable but bothersome AEs | |
| What to do with a patient who had not had a prior nephrectomy or evidence of metastatic disease but lesions remain in the kidneys |
EMEA-ONC-26-00048 / March 2026
The impact of disease burden: Understanding patient priorities in aRCC
Understanding patient expectations and clinicians' goals in favourable risk aRCC patients
Combination therapeutic strategies for aRCC patients with bone metastases
Non-clear cell renal cell carcinoma: Management of papillary RCC
Treatment management of favourable risk and very favourable risk patients
Managing cardiotoxicities for RCC treatment – Cardiologist’s perspective
Managing gastrotoxicities for RCC treatment – Gastroenterologist's perspective
Patient expectations and shared decision making in aRCC
Safety and quality of life assessment, how do they impact patient decision? KCCure survey – part B
Do patients and doctors treatment aspirations align? KCCure survey – part A
